Sun and MSI to collaborate on on-line drug discoveryLa Jolla 22 Aug 2000 Sun Microsystems and Molecular Simulations a wholly owned subsidiary of Pharmacopeia strted a collaboration to deliver advanced dot-com grade solutions spanning the drug discovery pipeline. Sun and MSI will enable cheminformatics and bioinformatics researchers to deploy MSI's solutions across networked environments and through application service providers (ASPs). The collaboration aims to open new markets for MSI's bioinformatics and structural biology products.
MSI, a cheminformatics software provider with licenses in most
major pharmaceutical companies worldwide, has named Solaris as a premier
platform for product development and deployment. To support the
extension of MSI's technologies, Sun is working closely with MSI to port
MSI's MODELER, SeqFold, CHARMm, DelPhi, and CNX products onto the
Solaris platform.
By porting to Solaris and using the Sun platform for development, MSI
will be able to offer its customers enterprise-wide deployment of its
solutions through a client-server model. In addition, MSI's adoption of
the Sun platform will enable the company to provide thousands of
informatics professionals worldwide access to its solutions through
Sun-powered ASPs.
Molecular Simulations is a provider of
simulation software for predicting the the structure and properties of
biological and chemical systems. Its software helps the world's
industrial research teams to solve commercially significant
problems and accelerate product discovery and development.
Ad Emmen |
 |